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Abstract
Aim:

To review the initial effectiveness of bovine lipid extract surfactant (BLES) for the

treatment of respiratory distress syndrome in preterm infants.

Methods and results:

A retrospective review of data collected from infants born <37‐week

gestation with respiratory distress syndrome treated with BLES between February 1, 2015 and
March 1, 2016. Data were analyzed to determine the timing of initial dose, the length of time
to wean the fraction of inspired oxygen (FiO2) concentration to 0.21 following initial dose, and
the number of repeated doses given during hospital admission. Infants were subgrouped by
gestational age stratum, 230 to 276 weeks (group 1), 280 to 316 weeks (group 2), and 320 to
366 weeks (group 3). Ninety‐eight infants received the surfactant during the study period. After
applying exclusion criteria, 77 infants were analyzed. Mean (SD) gestational age was 28 (4) weeks,
and mean (SD) birth weight was 1250 (602) g. Initial dose of BLES was given at a median (interquartile range) time of 29 (19‐43) minutes in group 1, 150 (20‐615) minutes in group 2, and 990
(53‐2025) minutes in group 3. Median (interquartile range) length of time to wean the FiO2 concentration to 0.21 was 14 (5‐56) minutes, 10 (5‐53) minutes, and 10 (5‐38) minutes in groups 1, 2,
and 3, respectively. Ten infants required repeated doses.

Conclusion:

Given the rapid response of BLES in all the groups, careful monitoring of

ventilator parameters is paramount to allow for rapid weaning and early extubation to avoid lung
injury associated with mechanical ventilation.
KEY W ORDS
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and volume adminstration.7,8 While numerous randomized con-

I N T RO D U CT I O N

trolled trials have compared different animal‐derived preparations,
Surfactant replacement therapy reduces mortality and morbidity in
1-5

preterm infants with respiratory distress syndrome (RDS).

There

it remains unclear whether significant differences in clinical outcomes exist among them.5,9

are 2 types of surfactants: animal derived and protein‐free

Bovine lipid extract surfactant (BLES Biochemicals, London,

synthetic. Although both surfactant types are effective in the treat-

Canada) is commonly used to treat RDS in premature infants in

ment and prevention of RDS, meta‐analyses have reported early

neonatal intensive care units (NICUs) across Canada, India, South

improvement in ventilator support, improved mortality rates, and

Africa, Iran, Saudi Arabia, Bolivia, and Chile. It is a natural extract of

reduced rates of pneumothoraces with treatment with animal‐

bovine pulmonary surfactant,9,10 containing 1% SP‐B and SP‐C and a

6

derived surfactants, compared with synthetic products.

Animal‐

phospholipid concentration of 27 mg/mL. Despite the popular use of

derived surfactants differ in their phospholipids, surfactant proteins

BLES, there are limited published trials for its use in the treatment of

B and C, and plasmalogens composition, as well as their viscosity

RDS in preterm infants.11,12 To our knowledge, there have not been
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any clinical studies specifically evaluating the immediate changes in
fraction of inspired oxygen (FiO2) following administration of BLES.
Understanding immediate response times of a specific surfactant is
important, to allow for rapid weaning of ventilator parameters and
early extubation onto noninvasive ventilator support, to ultimately
avoid lung injury associated with ongoing mechanical ventilation. Our
aim was to review the initial response of BLES by describing (1) the
timing of the initial dose, (2) the length of time to wean the FiO2 concentration to 0.21 following initial dose only, and (3) the number of
repeated doses given during hospital admission, for the treatment of
RDS in premature infants.

2.2
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Data collection
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The data were collected for each infant who received BLES either in
the resuscitation room or in the NICU, by respiratory therapists. The
following characteristics were collected from each infant: gestational
age, birth weight (grams), clinical diagnosis, initial timing of BLES
administration (minutes from birth), length of time to wean the FiO2
concentration to 0.21 following initial dose of surfactant replacement
therapy, and number of repeated doses given during hospital admission. Only infants who were able to wean the FiO2 concentration to
0.21 after their initial dose were included in the main data analysis.
Maternal characteristics were unavailable and were not collected.
To assess the effect of gestational age, infants were subgrouped

2
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|

by gestational age stratum: 230‐ to 276‐week gestation (extreme preterm: group 1), 280‐ to 316‐week gestation (very preterm: group 2),

2.1

|

Design and participants

and 320‐ to 366‐week gestation (group 3). Infants born ≥370‐week
gestation who received BLES therapy were excluded from the study.

We performed a retrospective analysis of data of all preterm infants
born between 230‐ and 366‐week gestation, admitted to the NICU at
London Health Sciences Centre, London, Canada, with a diagnosis of

2.3

RDS, and treated with BLES administration (5 mL/kg). The data were

The statistical analysis was performed using SPSS v.24 (IBM Corp,

collected from a single‐study center, from February 1, 2015 until

Armonk, New York). The data were presented as mean ± standard

March 1, 2016. A diagnosis of RDS was clinical (tachypnea, intercostal

deviation (SD), median ± interquartile range (IQR), and number of

retractions, nasal flaring, grunting, and an increasing FiO2 requirement

infants (%). Comparisons between gestational age subgroups were

to maintain oxygen saturation greater than 90%) and/or radiological.

evaluated using Kruskal‐Wallis test. Statistical significance was defined

The local evidence‐based practice guideline for the management

Statistical analysis
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as a P value < .05.

of RDS was followed to determine which infants received BLES.13

The study was approved by the Research Ethics Board at Western

The guideline includes all infants born less than 37‐week gestation at

University, London, Ontario, Canada. Individual signed consent is not

risk of developing RDS. Infants are resuscitated according to the

required to be obtained from patients/guardians for retrospective

Neonatal Resuscitation Program guidelines.14 Following resuscitation,

data/chart review, according to the Research Ethics Board guidelines.

each infant is assessed to determine which respiratory management

The data were extracted anonymously, with no identifiers. All parents

strategy is the most appropriate.

are made aware on admission that our institution is a teaching/academic hospital and that their infant's data may be used for research.

1. No respiratory support: The infant does not require any supplemental oxygen or does not show any signs of increased work of
breathing postresuscitation.
2. Nasal continuous positive airway pressure (NCPAP): If the infant
shows signs of increased work of breathing and/or requires supplemental oxygen therapy postresuscitation, the infant is given a
trial of NCPAP for a minimum of 10 minutes. If the FiO2 on
NCPAP is <0.3 in the resuscitation room, the infant is transferred
to the NICU on NCPAP. If the FiO2 increases to ≥0.4 on NCPAP in
the NICU, the infant is considered for BLES administration.
3. Intubate surfactant extubate: If the FiO2 is ≥0.3 after a trial of
NCPAP in the resuscitation room, the infant is eligible for
intubate‐surfactant‐extubate method.

3
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RESULTS

Ninety‐eight infants born between 230‐ and 366‐week gestation with
a diagnosis of RDS were treated with BLES during the study period
(Figure 1). Twenty‐one infants were excluded in the initial analysis.
Sixteen infants had incomplete data collected. Five infants had ongoing
oxygen requirements and were unable to wean the FiO2 concentration
to 0.21 following their initial dose of BLES; their mean (SD) gestational
age was 28 (3) weeks, and the mean (SD) birth weight was 1342
(425) g.
Data from 77 infants were analyzed. Mean (SD) gestational age
was 28 (4) weeks, and the mean (SD) birth weight was 1250

4. Surfactant and ongoing mechanical ventilation: If the infant is

(602) g. The initial dose of BLES was given at a median (IQR) time

intubated and does not have an adequate respiratory effect and/

of 40 (22‐270) minutes after birth, and the median (IQR) length of

or FiO2 is >0.3 following BLES administration and/or clinically

time to wean the FiO2 concentration to 0.21 was 10 (5‐45) minutes

unstable, the infant is not extubated following surfactant delivery.

in all infants.

Infants who are intubated during the resuscitation only, receive

based on a hypothesis that the smaller premature infants may show

surfactant replacement therapy if a diagnosis of RDS is made.

a different response to surfactant compared with the larger, more

Repeated doses of BLES administration is considered if the FiO2

mature infants. Forty infants (52%) were in the extreme preterm

concentration is persistently >0.3 within the first 48 hours of life.

group, mean (SD) birth weight 816 (190) g; 21 (27%) were in the very

Infants were subgrouped by 3 gestational age stratum. This was

STOCKLEY
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Flow diagram of results. BLES, bovine lipid extract surfactant; IQR, interquartile range; SD, standard deviation

preterm group, mean (SD) birth weight 1420 (374) g; and 16 (21%)

length of time to wean the FiO2 concentration to 0.21 was 14 (5‐-

infants were born ≥32 ‐week gestation, mean (SD) birth weight

56) minutes in the extreme preterm group, 10 (5‐53) minutes in the

2112 (470) g. A significant difference was observed in the timing of

very preterm group, and 10 (5‐38) minutes in infants born ≥320‐week

the initial dose of BLES between each group. In the extreme preterm

gestation (Figure 2).

0

group, the initial dose of BLES was given at a median (IQR) time of 29

Eighty‐eight percent (72/82) of preterm infants required only a

(19‐43) minutes after birth, compared with 150 (20‐615) minutes in

single dose of BLES to wean the FiO2 concentration to 0.21. Ten

the very preterm group and 990 (53‐2025) minutes in infants born

infants required repeated doses. Among them, 5 infants initially

≥320‐week gestation (P < .001). However, no statistical significant dif-

weaned to 0.21 but subsequently developed an oxygen requirement

ference was observed in the length of time to wean to 0.21 following

and received further doses of BLES within 48 hours of birth. Four

initial dose, among the groups. In the extreme group, the median (IQR)

infants were in the extreme preterm group, and 1 infant was born

FIGURE 2

Response time of bovine lipid extract surfactant in all preterm infants

4 of 5

STOCKLEY

&C?JRFѥ1AGCLACѥ0CNMPRQ

ET AL.

≥320‐week gestation. Within the extreme preterm group, 3 infants

Our review of data had some methodological limitations. First, this

received 2 repeated doses of BLES and 1 infant received 1 repeated

was a retrospective descriptive review, lacking a comparable control

BLES dose. The remaining 5 infants who required repeated doses

group. We also had a small sample size, which may result in lower

had prolonged ongoing oxygen requirements following their initial

statistical power to detect differences between groups. Finally, we

dose of BLES and required 1 repeated dose within 48 hours of birth.

did not analyze significant characteristics of the studied participants,

Among them, 4 infants were in the extreme preterm group, and 1

such as sex, multiple gestation, perinatal asphyxia, Apgar scores, and

infant was born ≥320‐week gestation.

maternal risk factors (preterm prolonged rupture of membrane,
chorioamnionitis, mode of delivery, and prenatal steroids); these
factors may have affected our results.

4
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DISCUSSION

Our study is the first to describe the length of time to wean the FiO2
concentration to 0.21 following the initial dose of BLES administration
in the treatment of RDS in preterm infants. All 3 groups, based on
gestational age, showed a fast response to BLES, emphasizing the
importance of careful monitoring of ventilator parameters to allow
for rapid weaning and early extubation onto noninvasive ventilator
support in infants of all gestations, to avoid pulmonary complications.
Extreme preterm infants received their initial dose of BLES significantly earlier in their RDS management compared with infants born
≥280‐week gestation. This can be explained by the degree of RDS:
Extreme preterm infants are more likely to have severe RDS at birth
compared with infants with a higher gestational age. The local
evidence‐based practice guideline may have also played a role, as

5
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CO NC LUSIO N

Extreme preterm infants received their initial dose of BLES earlier in
their RDS management. Fast onset of action with rapid weaning of
the FiO2 concentration to 0.21 was described in all 3 groups of
preterm infants following the administration of BLES for the treatment
of RDS. Careful monitoring of ventilator parameters following BLES
administration is therefore paramount to allow for rapid weaning and
early extubation onto noninvasive ventilator support, to prevent lung
injury associated with mechanical ventilation.
ACKNOWLEDGEMENT/FUNDING
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criteria for BLES therapy varied according to the location of the infant
(resuscitation room or NICU).

CONFLIC T OF IN TE RE ST S

There are only 2 published trials comparing BLES with another
animal‐derived surfactant. The initial study of Lam et al11 compared

BLES Biochemical Inc did not fund the study nor had any influence in

the clinical response by oxygenation indices of preterm infants with

the design, data collection, and interpretation of the results. The

RDS, randomized to receive either beractant or BLES. Infants in the

surfactant maker did not review or revised the manuscript submitted

BLES group demonstrated a faster onset of action with a significantly

for publication.

lower oxygenation indices within the first 8 hours after initial dose
and fewer days of mechanical ventilation. Lemyre et al12 compared
the efficacy and safety of poractant alfa and BLES in infants <32‐week
gestational age. They found no statistically significant difference in the
proportion of infants alive and extubated within 48 hours, rates of
bronchopulmonary dysplasia, mortality, or complications. However,
duration of oxygen therapy was significantly reduced in infants who
received poractant alfa.
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Despite the limited data on BLES, there are numerous trials comparing the immediate response of different animal‐derived surfactants
by means of changes in FiO2 at various time points.8,15-20 poractant
alfa has been extensively studied and has been found to result in
greater improvement in oxygenation and require fewer repeated doses
when compared with Beractant.8,15,16,18 However, there are no studies
specifically evaluating the length of time to wean the FiO2 concentration to 0.21 following the administration of surfactant.
A retrospective review of our data found that 12% (10/82) of
infants required repeated doses of BLES. Both Lam et al11and Lemyre
12

et al

reported redosing and found no significant difference between

groups. However, they did observe higher rates than in our review of
data. Thirty‐four percent (10/29) of infants required repeated doses
of BLES compared with 58% (18/31) in the Beractant group,11 and
20% (9/45) of infants required repeated doses of BLES compared with
19% (8/42) in the poractant alfa group.12
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